N-Power Medicine Raises $32M for Oncology Trial Reform

N-Power Medicine has closed a $32M Series B financing to expand its community oncology research network and accelerate adoption of its Prospective External Control Arm platform, known as ProECA. Labcorp Venture Fund joined as a new strategic investor, alongside continued participation from Merck Global Health Innovation Fund, Innovatus Capital Partners, and an unnamed U.S.-based biotech investor.

The September 1, 2026 announcement extends a financing story that began with an initial Series B close in 2024. That earlier close brought N-Power Medicine's reported total funding to $72M; the company now says it has raised more than $100M. The newest release does not disclose valuation, ownership percentages, or individual investor allocations.

The larger story is not simply another healthcare funding round. N-Power Medicine is trying to move clinical research into the community oncology practices where most cancer patients already receive care, while building evidence that can support faster and potentially smaller drug-development programs.

What N-Power Medicine Announced

N-Power Medicine said the $32M financing will support expansion of its community oncology network, deeper pharmaceutical partnerships, and continued product development. Labcorp Venture Fund is the new strategic investor. Merck Global Health Innovation Fund, Innovatus Capital Partners, and an unnamed U.S. biotech investor continued their participation.

N-Power Medicine was founded in 2021 by pharmaceutical drug-development executives. Mark Lee, MD, PhD, is co-founder and CEO. Christer Svedman, MD, PhD, is a co-founder and clinical-science leader. The company is headquartered in Redwood City, California.

N-Power's current financing is part of the same broad Series B progression it announced in July 2024. The earlier initial close was led by Merck GHI and brought total funding at the time to $72M. The company's current website reports more than $100M raised to date, which is consistent with the addition of the newly announced $32M without requiring an invented lifetime total.

Why Community Oncology Is the Operating Problem

Cancer drug development depends on patients, investigators, consistent data, and tightly managed protocols. Those elements do not always meet in the same place. Many patients receive care in community practices, while a large share of clinical research remains concentrated in academic medical centers.

That separation creates a participation problem and an evidence problem. Patients may face travel, schedule, and eligibility burdens. Community oncologists may lack the staff, technology, and administrative capacity required to make research part of everyday care. Drug developers can struggle to enroll representative populations quickly enough to answer important questions.

N-Power Medicine is building an always-on research network intended to make community care and prospective evidence generation part of one system. Its Kaleido Registry collects standardized information from routine oncology care. The ProECA platform is designed to create external control arms prospectively, according to a defined protocol, rather than assembling a comparison cohort after the fact from whatever data happened to be available.

How ProECA Changes the Trial Design Conversation

An external control arm uses patient data from outside the investigational treatment group as a comparator. In principle, that can reduce the number of participants assigned to a conventional control arm, shorten enrollment, and improve the odds that a participant receives the investigational therapy. In practice, retrospective external controls can carry missing data, inconsistent assessments, selection bias, and differences in treatment patterns that make comparisons unreliable.

N-Power's prospective model tries to address those weaknesses before data collection begins. The company says ProECA programs align eligibility criteria, imaging schedules, next-generation sequencing, biosamples, endpoints, and follow-up with the needs of an active development program. Patients receive standard-of-care therapy in their community setting while the comparison data are generated with trial-grade discipline.

A recent Journal of Clinical Oncology paper co-authored by Lee and Svedman argues that prospective external controls could shorten enrollment and reduce development costs in some hybrid Phase 2 designs. The same paper is explicit about the boundary: robust validation, governance, traceability, endpoint alignment, and bias analysis are required, and residual confounding cannot be eliminated simply because the data are collected prospectively.

That caution is consistent with the FDA Oncology Real World Evidence Program, which emphasizes fit-for-purpose data and rigorous methods when real-world evidence is used in oncology development.

The Evidence N-Power Has Built So Far

N-Power Medicine says its first ProECA program, focused on non-small cell lung cancer, is operational at more than 40 sites across several large community-based health systems. Multiple pharmaceutical and biotechnology partners are using the program for early-development and Phase 4 work. The company plans to launch colorectal cancer and prostate cancer ProECA programs later in 2026.

The network has expanded through partnerships and acquisition. N-Power acquired Syapse Holdings in January 2025, adding a community-based oncology research network and data infrastructure. In January 2026, the company announced a collaboration with AdventHealth spanning cancer-care locations in Colorado, Kansas, Georgia, and Florida.

These are meaningful operating signals, but they are not substitutes for program-level validation. N-Power has not publicly disclosed customer-by-customer results, independent measures of trial acceleration, intervention rates, or a comprehensive economic analysis of ProECA deployments.

Why Labcorp's Investment Matters

Labcorp Venture Fund's participation gives the financing a strategic dimension. Labcorp operates across diagnostics, laboratory services, clinical development, data, and patient access. Its venture fund specifically invests in areas that include real-world evidence, clinical-trial recruitment, decentralization, optimization, and data exchange.

N-Power's product sits directly inside that map. Prospective external controls depend on more than software. They require reliable testing, standardized data, operational support, protocol adherence, and enough clinical infrastructure to keep research intact as it moves through ordinary patient care.

The investment does not prove a commercial partnership beyond what has been announced. It does show that another large healthcare operator sees strategic value in a model designed to bring drug-development evidence closer to community practice.

What the $32M Needs to Prove

The financing gives N-Power Medicine room to expand its network and carry ProECA into more cancer types. The company must now demonstrate that prospective external controls can deliver consistent data quality across different practices, patient populations, sponsors, and indications without creating a new administrative burden for community oncologists.

The strongest version of the model could improve several relationships at once. Drug developers could make earlier decisions with fewer control patients. Practices could participate in research without rebuilding themselves as academic trial centers. Patients could encounter more research opportunities where they already receive treatment.

Those benefits depend on execution that survives contact with the clinic. Every protocol requirement has to become a reliable workflow. Every data point has to remain traceable. Every efficiency claim has to coexist with the scientific obligation to understand bias and uncertainty.

N-Power Medicine's $32M Series B buys more than network growth. It funds an attempt to make clinical rigor portable. The market will learn whether that portability can hold as more community practices, drug developers, and patients enter the same evidence system.